Journal article
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
B Ley, AW Satyagraha, H Rahmat, ME von Fricken, NM Douglas, DA Pfeffer, F Espino, L von Seidlein, G Henriques, NN Oo, D Menard, S Parikh, G Bancone, A Karahalios, RN Price
Plos Medicine | PUBLIC LIBRARY SCIENCE | Published : 2019
Abstract
Background To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994). Methods and findings Articles published on PubMed between 1 January 2011 and 27 September ..
View full abstractGrants
Awarded by Menzies School of Health Research
Funding Acknowledgements
No specific funding was received for this study. However, BL is funded through a fellowship from the Menzies School of Health Research, Darwin, Australia. BL and RNP are funded by the Australian Department of Foreign Affairs and Trade (74431) and the Bill & Melinda Gates Foundation (OPP1054404 and OPP1164105). RNP is also funded by the Wellcome Trust (Senior Fellowship in Clinical Science, 200909) and the Australian Centre for Research Excellence on Malaria Elimination (APP 1134989). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.